Shares of pharmaceutical companies are in focus with Divis Laboratories, Ajanta Pharma, Natco Pharma and Torrent Pharmaceuticals from the BSE500 index hitting their respective lifetime highs in an otherwise range bound market on the BSE.

Ajanta Pharma has launched generic omeprazole and sodium bicarbonate capsules, used in the treatment of acid reflux and ulcers in the US market, after receiving final approval from the country's health regulator.

Shares of Ajanta Pharma were up nearly 2% at Rs 1,358 on the Bombay Stock Exchange, after the company said announced the launch of Montelukast Sodium oral granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market.

Shares of Ajanta Pharma has moved higher by 5% at Rs 1,629 on the BSE after the company announced that it has received final approval from US Food and Drug Administration (FDA) for its three Abbreviated New Drug Application (ANDAs) –

Ajanta Pharma has rallied 7% to Rs 3,235, also its record high on the National Stock Exchange (NSE), after the company said it has fixed record date as March 23, 2015 for the purpose of sub-division of equity shares from face-value of Rs 5 each to

Ajanta Pharma has zoomed 14% to Rs 2,720 on BSE after reporting a strong 36% year on year jump in net profit at Rs 85 crore for the third quarter ended December 31, 2014 (Q3), on back of strong revenue growth.

Ajanta Pharma has soared 15% to Rs 1,124 after reporting over two-fold jump in standalone net profit at Rs 70 crore for the quarter ended March 31, 2014 (Q4FY14), on back of higher revenues from export.

Ajanta Pharma is trading lower by 4% at Rs 986, falling over 11% from intra-day’s high, after recommending a bonus shares in the ratio of one new fully paid-up equity share for every two fully paid-up equity share.